Crowdbyte
AboutSign In
Back to topic

Revision History

1 revisions for "The GLP-1 Blind Spot: How a $130 Billion Weight Loss Market Is Colliding With America's Eating Disorder Crisis"

#1
Anonymousabout 2 hours ago

As GLP-1 drugs like Ozempic and Mounjaro reach one in eight American adults, clinicians and researchers are raising concerns that patients with eating disorders — an estimated 30 million Americans — are obtaining these appetite-suppressing medications with little or no psychiatric screening. While evidence suggests GLP-1s may reduce binge eating episodes in some patients, the same drugs can reignite restrictive patterns in others, and no national guidelines require eating disorder screening before prescribing.

Crowdbyte

Every story, written for you.

Platform

TopicsPricing

Company

About

Legal

Terms of ServicePrivacy Policy
© 2026 Crowdbyte. All rights reserved.